Cognitively unimpaired individuals with a low burden of Aß pathology have a distinct CSF biomarker profile.

ABSTRACT

BACKGROUND: Understanding the changes that occur in the transitional stage between absent and overt amyloid-ß (Aß) pathology within the Alzheimer's continuum is crucial to develop therapeutic and preventive strategies. The objective of this study is to test whether cognitively unimpaired individuals with a low burden of Aß pathology have a distinct CSF, structural, and functional neuroimaging biomarker profile. METHODS: Cross-sectional study of 318 middle-aged, cognitively unimpaired individuals from the ALFA+ cohort. We measured CSF Aß42/40, phosphorylated tau (p-tau), total tau (t-tau), neurofilament light (NfL), neurogranin, sTREM2, YKL40, GFAP, IL6, S100B, and α-synuclein. Participants also underwent cognitive assessments, APOE genotyping, structural MRI, [18F]-FDG, and [18F]-flutemetamol PET. To ensure the robustness of our results, we used three definitions of low burden of Aß pathology (1) positive CSF Aß42/40 and < 30 Centiloids in Aß PET, (2) positive CSF Aß42/40 and negative Aß PET visual read, and (3) 20-40 Centiloid range in Aß PET. We tested CSF and neuroimaging biomarker differences between the low burden group and the corresponding Aß-negative group, adjusted by age and sex. RESULTS: The prevalence and demographic characteristics of the low burden group differed between the three definitions. CSF p-tau and t-tau were increased in the low burden group compared to the Aß-negative in all definitions. CSF neurogranin was increased in the low burden group definitions 1 and 3, while CSF NfL was only increased in the low burden group definition 1. None of the defined low burden groups showed signs of atrophy or glucose hypometabolism. Instead, we found slight increases in cortical thickness and metabolism in definition 2. CONCLUSIONS: There are biologically meaningful Aß-downstream effects in individuals with a low burden of Aß pathology, while structural and functional changes are still subtle or absent. These findings support considering individuals with a low burden of Aß pathology for clinical trials. TRIAL REGISTRATION NCT02485730.